In the study by Yang et al. [178], PEG modified GO-based nanoparticles with a monoclonal antibody modification were tested against follicle-stimulating hormone receptor (FSHR) to specifically target metastatic nodules of MDA-MB-231 breast cancer cells within the lungs. Here, FSHR is linked to breast carcinoma.